LIXTE Biotechnology (LIXT) announced a collaboration with Roche (RHHBY) and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metastatic colon cancer. As part of the new clinical trial, listed as NCT06012734 at clinicaltrials.gov, LIXTE will provide its lead compound, LB-100, and Roche will provide atezolizumab and financial support.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIXT:
- Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
- Lixte Biotechnology announces publication of preclinical data in EMBO Reports
- Lixte Biotechnology Appoints New Chief Medical Officer
- Lixte Biotechnology appoints Jan Schellens as CMO
- LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer